Baxter International Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Baxter International Inc. on December 20, 2019. The filing discloses the entry into new material definitive credit agreements and the termination of prior credit facilities.
Key Financial Metrics and Debt Structure
The filing details the establishment of two new revolving credit facilities:
- U.S. Credit Agreement: A $2.0 billion five-year revolving credit agreement entered into on December 20, 2019. This facility is unsecured, denominated in U.S. Dollars, and bears variable interest rates. It includes an accordion feature allowing an increase of up to $1.0 billion, for a maximum commitment of $3.0 billion.
- Euro Credit Agreement: A €200 million five-year revolving credit agreement entered into on December 20, 2019, by Baxter Healthcare SA and Baxter World Trade SPRL. This facility is unsecured, denominated in Euros (or other eligible currencies), and bears variable interest rates. It includes an accordion feature allowing an increase of up to €100 million, for a maximum commitment of €300 million.
Both agreements contain financial covenants, including a net leverage ratio covenant, and customary events of default. The filing does not provide specific values for revenue, profit, cash flow, or current liquidity positions.
Material Changes Versus Prior Period
The new credit agreements replace existing facilities that were terminated on December 20, 2019:
- The U.S. agreement replaces a $1.5 billion five-year revolving credit agreement dated July 1, 2015.
- The Euro agreement replaces a €200 million revolving credit agreement dated July 1, 2015.
The primary material change is the increase in the U.S. credit facility capacity from $1.5 billion to $2.0 billion (with potential expansion to $3.0 billion), while the Euro facility capacity remains at €200 million (with potential expansion to €300 million).
Guidance, Outlook, and Risks
The filing does not contain management guidance, financial outlook, or commentary on future performance. The primary risks disclosed relate to the terms of the new credit agreements, specifically the net leverage ratio covenants and events of default which could impact the company's ability to borrow if financial metrics are not maintained.
Key Facts for Investor Verification
- Verify the specific terms of the net leverage ratio covenants in the attached Credit Agreements (Exhibits 10.1 and 10.2).
- Confirm the current utilization levels of the new $2.0 billion U.S. and €200 million Euro facilities.
- Review the company's most recent 10-K or 10-Q to assess current liquidity and debt levels in the context of the new leverage covenants.
- Note that the filing does not disclose any immediate drawdowns on these facilities.